Skip to main content

Large Scale Biology Adds Nine Patents to IP Portfolio

NEW YORK, Nov. 15 – Large Scale Biology was issued nine new patents the company plans to use in its proteomics, functional genomics, and biomanufacturing operations, the company announced Thursday.

The patents issued to the Vacaville, Calif.-based company include US Patent No 6,254,834 for, according to the company, “distinguishing infectious agents, for identifying known viral pathogens, and for discovering and characterizing unknown viral pathogens.”

“Expanding our rights in the area of viral detection enables us to develop new means of identifying and tracking infections earlier, with important public health safety implications, as well as potential savings for the public and private medical care system,” John Fowler, president of Large Scale Biology, said in a statement.

Other patents include technology applicable to automated 2-D gel electrophoresis, agricultural genomics, and biomanufacturing, including extracting sugars and pharmaceutical proteins from plants.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.